Hims & Hers has agreed to of­fer No­vo Nordisk’s GLP-1 obe­si­ty and di­a­betes treat­ments on its web­site and lim­it ac­cess to com­pound­ed ver­sions. The move seem­ing­ly ends a con­flict that es­ca­lat­ed last month when the tele­health com­pa­ny launched a com­pound­ed ver­sion of No­vo’s new­ly ap­proved We­govy weight loss pill, draw­ing a law­suit from the phar­ma gi­ant and in­tense scruti­ny from reg­u­la­tors in­clud­ing the FDA and HHS...